Literature DB >> 18301032

Early macular morphological changes following plaque radiotherapy for uveal melanoma.

Noel Horgan1, Carol L Shields, Arman Mashayekhi, Luiz F Teixeira, Miguel A Materin, Jerry A Shields.   

Abstract

PURPOSE: To evaluate the time of onset and risk factors for the development of macular edema following plaque radiotherapy for uveal melanoma, using optical coherence tomography (OCT).
METHODS: This observational case series included 135 consecutive patients with uveal melanoma treated with Iodine(125) plaque radiotherapy and adjunctive transpupillary thermotherapy (TTT) laser. Patients were evaluated at baseline and 6-month intervals following treatment using ophthalmoscopy, B-scan ultrasonography, fundus photography, and OCT.
RESULTS: Median follow-up was 24 months. The mean time to onset of macular edema by OCT was 12 months. Median best-corrected logMAR visual acuity at the time of onset of OCT-evident macular edema was 0.3 (equivalent to 20/40 Snellen). The development of OCT-evident macular edema was significantly associated with maximum tumor thickness (P = 0.0016), largest tumor base (P < 0.0001), radiation dose, and dose-rate to the tumor base (P = 0.0315 and P = 0.0204, respectively). Neither radiation dose to the foveola nor treatment with adjunctive TTT laser was significantly associated with the development of macular edema.
CONCLUSIONS: OCT is useful in the early detection of radiation-induced macular edema, before clinical signs of radiation maculopathy develop and before substantial visual loss occurs. The development of macular edema is significantly associated with larger initial tumor size.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18301032     DOI: 10.1097/IAE.0b013e31814b1b75

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  18 in total

1.  Evaluation of early changes of macular function and morphology by multifocal electroretinograms in patients with nasopharyngeal carcinoma after radiotherapy.

Authors:  Haijun Gong; Yuanlin Tang; Jianhui Xiao; Yimin Liu; Rui Zeng; Zijing Li; Si Zhang; Yuqing Lan
Journal:  Doc Ophthalmol       Date:  2019-02-09       Impact factor: 2.379

Review 2.  Early anti-VEGF treatment for radiation maculopathy and optic neuropathy: lessons learned.

Authors:  Brittany E Powell; Kimberly J Chin; Paul T Finger
Journal:  Eye (Lond)       Date:  2022-08-16       Impact factor: 4.456

3.  Visual Outcome at 4 Years Following Plaque Radiotherapy and Prophylactic Intravitreal Bevacizumab (Every 4 Months for 2 Years) for Uveal Melanoma: Comparison With Nonrandomized Historical Control Individuals.

Authors:  Carol L Shields; Lauren A Dalvin; Michael Chang; Mehdi Mazloumi; Patricia Fortin; Mark McGarrey; Andrei Martin; Antonio Yaghy; Xiaolu Yang; Pornpattana Vichitvejpaisal; Arman Mashayekhi; Jerry A Shields
Journal:  JAMA Ophthalmol       Date:  2020-02-01       Impact factor: 7.389

4.  Quantifying Subclinical and Longitudinal Microvascular Changes Following Episcleral Plaque Brachytherapy Using Spectral Domain-Optical Coherence Tomography Angiography.

Authors:  Kyle M Green; Brian C Toy; Bright S Ashimatey; Debarshi Mustafi; Richard L Jennelle; Melvin A Astrahan; Zhongdi Chu; Ruikang K Wang; Jonathan Kim; Jesse L Berry; Amir H Kashani
Journal:  J Vitreoretin Dis       Date:  2020-08-13

Review 5.  Off-Label Use of 0.19 mg Fluocinolone Acetonide Intravitreal Implant: A Systematic Review.

Authors:  Flávio Ribeiro; Manuel S Falcão
Journal:  J Ophthalmol       Date:  2021-05-17       Impact factor: 1.909

6.  Optical coherence tomography of retinal and choroidal tumors.

Authors:  Emil Anthony T Say; Sanket U Shah; Sandor Ferenczy; Carol L Shields
Journal:  J Ophthalmol       Date:  2011-07-18       Impact factor: 1.909

7.  Intravitreal Aflibercept as Rescue Therapy for Post-Radiation Cystoid Macular Edema Resistant to Intravitreal Bevacizumab: Outcomes at 1 Year.

Authors:  Mohammed Ali Khan; Arman Mashayekhi; Jerry A Shields; Carol L Shields
Journal:  Ocul Oncol Pathol       Date:  2017-05-06

8.  High-Dose (2.5 mg) Intravitreal Bevacizumab as Rescue Therapy for Persistent Postradiation Cystoid Macular Edema.

Authors:  Mohammed Ali Khan; Arman Mashayekhi; Kyle Ferguson; Jerry A Shields; Carol L Shields
Journal:  Ocul Oncol Pathol       Date:  2017-01-27

9.  Early SD-OCT diagnosis followed by prompt treatment of radiation maculopathy using intravitreal bevacizumab maintains functional visual acuity.

Authors:  Nisha V Shah; Samuel K Houston; Arnold M Markoe; William Feuer; Timothy G Murray
Journal:  Clin Ophthalmol       Date:  2012-10-29

10.  Optical coherence tomography of retinal and choroidal tumors.

Authors:  Emil Anthony T Say; Sanket U Shah; Sandor Ferenczy; Carol L Shields
Journal:  J Ophthalmol       Date:  2011-06-08       Impact factor: 1.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.